CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Memorial Sloan Kettering Cancer Center
Amgen
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Pfizer
Amgen
National Cancer Institute, Egypt
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Kousai Bio Co., Ltd.
Thomas Jefferson University
Baylor College of Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BioNTech SE
University of Calgary
Lyell Immunopharma, Inc.
BeOne Medicines
Children's Hospital of Philadelphia
Institute of Hematology & Blood Diseases Hospital, China
The First Affiliated Hospital of Soochow University
Institut Claudius Regaud
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Yale University
UNC Lineberger Comprehensive Cancer Center
Fundación de investigación HM
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Immatics US, Inc.
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Pfizer
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Baylor College of Medicine
St. Jude Children's Research Hospital
University of Pittsburgh
National Cancer Centre, Singapore
Beijing Biotech
Gilead Sciences
Memorial Sloan Kettering Cancer Center
AVEO Pharmaceuticals, Inc.
The General Hospital of Western Theater Command
Global Coalition for Adaptive Research